Sinopharm Unit Gets OK for Clinical Trials of mRNA COVID Vaccine

Sinopharm said on Friday its biotech unit has received regulatory approval for clinical trials of its mRNA COVID-19 vaccine targeting the Omicron variant.
Reuters Health Information
Sinopharm said on Friday its biotech unit has received regulatory approval for clinical trials of its mRNA COVID-19 vaccine targeting the Omicron variant.
Reuters Health Information